Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Regn save search
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published: 2024-03-27 (Crawled : 23:00) - biospace.com/
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.78%
H: 0.4%
C: -0.49%
ren026 fda study
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.5%
OPT | $3.4 3.6K
|
Health Technology
|
| O: 0.0%
H: 4.76%
C: -0.85%
first trial
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.67 -0.04% 230K
|
Health Technology
| Email alert
Add to watchlist
trial potential
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials
Published: 2023-10-10 (Crawled : 07:00) - zailaboratory.com
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.28%
H: 1.11%
C: 0.66%
trials
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
Published: 2023-10-05 (Crawled : 13:30) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.0%
H: 2.04%
C: 1.98%
eylea macular trial injection results
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
Published: 2023-08-10 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.52%
H: 1.05%
C: 0.47%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.4%
H: 1.32%
C: 0.51%
macular trial results
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
Published: 2023-07-29 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.67 -0.04% 230K
|
Health Technology
| Email alert
Add to watchlist
macular trial results diabetic
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.05%
H: 1.33%
C: 0.38%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: 5.53%
H: 5.23%
C: -2.49%
disease alzheimer’s positive results
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
Published: 2023-06-27 (Crawled : 18:00) - globenewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -1.1%
H: 0.26%
C: -1.16%
macular trial results diabetic
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 1.67%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.0%
H: 0.24%
C: 0.01%
trial
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
Published: 2023-05-12 (Crawled : 11:00) - globenewswire.com
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 0.84%
H: 6.94%
C: 0.28%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.48%
H: 0.36%
C: -0.64%
candidate approval medical application trial therapeutics therapy
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
Published: 2023-03-23 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 5.54%
H: 0.96%
C: 0.96%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 6.53%
H: 0.56%
C: -0.54%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 7.34%
H: 0.77%
C: -0.53%
dupixent copd trial potential
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
Published: 2023-03-23 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 5.54%
H: 0.96%
C: 0.96%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 6.53%
H: 0.56%
C: -0.54%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 7.34%
H: 0.77%
C: -0.53%
dupixent copd potential
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
Published: 2023-01-24 (Crawled : 13:20) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: -0.15%
H: 18.49%
C: 15.32%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.15%
H: 0.18%
C: -0.48%
candidate application trial approval therapeutics therapy
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
Published: 2022-12-12 (Crawled : 23:00) - prnewswire.com
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 0.89%
H: 0.65%
C: -0.21%
cd20 trial response
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | News | $144.345 -0.56% 330K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | $893.67 -0.04% 230K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.